TGF-β1 and TIMP-4 regulate atrial fibrosis in atrial fibrillation secondary to rheumatic heart disease
Authors:
- 14 May 2015
- journal article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 406 (1-2) , 131-138
Abstract
To investigate the involvement of transforming growth factor-β1 (TGF-β1) and tissue inhibitor of metalloproteinase 4 (TIMP-4) in influencing the severity of atrial fibrosis in rheumatic heart disease (RHD) patients with atrial fibrillation (AF). The degree of myocardial fibrosis was evaluated using Masson staining. The expression levels of TGF-β1, TIMP-4, matrix metalloproteinase-2 (MMP-2), type I collagen, and type III collagen were estimated by Western blot analysis. Additionally, TGF-β1 and TIMP-4 mRNA levels were quantified by qRT-PCR. The effect of TGF-β1 stimulation on TIMP-4 expression was assessed by in vitro stimulation of freshly isolated human atrial fibroblasts with recombinant human TGF-β1, followed by Western blot analysis to detect changes in TIMP-4 levels. Masson stain revealed that the left atrial diameter and collagen volume fraction were obviously increased in AF patients, compared to sinus rhythm (SR) controls (both P < 0.05). Western blot analysis showed significantly elevated levels of the AF markers MMP-2, type I collagen, and type III collagen in the AF group, in comparison to the SR controls (all P < 0.05). In the AF group, TGF-β1 expression was relatively higher, while TIMP-4 expression was apparently lower than the SR group (all P < 0.05). TIMP-4 expression level showed a negative association with TGF-β1 expression level (r = −0.98, P < 0.01) and TGF-β1 stimulation of atrial fibroblasts led to a sharp decrease in TIMP-4 protein level. Increased TGF-β1 expression and decreased TIMP-4 expression correlated with atrial fibrosis and ECM changes in the atria of RHD patients with AF. Notably, TGF-β1 suppressed TIMP-4 expression, suggesting that selective TGF-β1 inhibitors may be useful therapeutic agents.Keywords
This publication has 30 references indexed in Scilit:
- Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1Cardiovascular Research, 2013
- Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathwayProceedings of the National Academy of Sciences, 2012
- Effects of Electrical and Structural Remodeling on Atrial Fibrillation Maintenance: A Simulation StudyPLOS Computational Biology, 2012
- Transforming growth factor (TGF)-β signaling in cardiac remodelingJournal of Molecular and Cellular Cardiology, 2011
- Biomarkers of Extracellular Matrix Metabolism (MMP-9 and TIMP-1) and Risk of Stroke, Myocardial Infarction, and Cause-Specific Mortality: Cohort StudyPLOS ONE, 2011
- TGF‐β1 Expression and Atrial Myocardium Fibrosis Increase in Atrial Fibrillation Secondary to Rheumatic Heart DiseaseClinical Cardiology, 2010
- MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure*Archives of Physiology and Biochemistry, 2010
- Extracellular matrix turnover and signaling during cardiac remodeling following MI: Causes and consequencesJournal of Molecular and Cellular Cardiology, 2010
- The fibrosis and atrial fibrillation: Is the transforming growth factor-β1 a candidate etiology of atrial fibrillationMedical Hypotheses, 2008
- Surface electrocardiogram in the detection of transmural myocardial ischemia during coronary artery occlusionThe American Journal of Cardiology, 1989